February 3, 2022
PAR-22-091- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
National Cancer Institute (NCI)
The purpose of this Notice is to correctly state the review locus for Funding Opportunity Announcement PAR-22-091, "Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)".
The following section of PAR-22-091 has been corrected:
Currently Reads:
Section V. Application Review Information, 2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the NCI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
Modified to Read (changes shown in bold italics):
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review (CSR), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
All other aspects of the FOA remain unchanged.
Scientific/Research Contact(s)
Miguel R. Ossandon, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email: [email protected]
Brian Sorg, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5712
Email: [email protected]
Yantian Zhang, Ph.D.
National Cancer Institute
Telephone: 240-276-5980
Email: [email protected]
David Jonathan Miller, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6810
Email: [email protected]
Zhong Chen, MD, PhD
National Institute Of Dental & Craniofacial Research (NIDCR)
Phone: 3015297083
E-mail: [email protected]
Xincheng Zheng (Ted), M.D, Ph.D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: (301) 594-4953
Email: [email protected]
and Human Services (HHS)
